Semaglutide is FDA-approved in the form of injections (Ozempic, Wegovy) or oral tablets (Rybelsus)
While mild cases may resolve without intervention or remain undiagnosed, more severe episodes can lead to serious complications, including abscesses, bowel perforation, or peritonitis conditions that require urgent medical attention [1]
Semaglutide appetite suppression timing follows a similar pattern to tirzepatide, with maximum effect occurring one to three days post-injection
Demonstration of the heterolytic O-O bond cleavage of putative nonheme iron(II)-OOH(R) complexes for Fenton and enzymatic reactions
Group 1 drivers (cars/motorcycles) must notify the DVLA if they have recurrent severe hypoglycaemia or impaired awareness
The gastrointestinal side effects commonly experienced by adults taking Ozempic raise theoretical questions about similar effects in infants, but again, no human data exist to confirm or refute these concerns